Health Benefits of Modificated Multiplatinum Derivatives as Strategies for Overcoming the Cisplatin Resistance
,
Abstract
No Abstract
1. Bai L, Gao C, Liu Q, et al (2017). Research progress in modern structure of plati-num complexes. Eur J Med Chem, 140(1): 349–82.
2. Wang K, Gao E (2014). Recent advances in multinuclear complexes as potential an-ticancer and DNA binding agents. Anti-Cancer Agents Med Chem, 14(1):147–69.
3. Gibson D (2016). Platinum (IV) anticancer prodrugs – hypotheses and facts. Dalton Trans, 45(33): 12983–91.
4. Baudino TA (2015). Targeted cancer thera-py: the next generation of cancer treat-ment. Curr Drug Discov Technol, 12(1): 3–20.
5. Patra JK, Das G, Fraceto, LF, et al (2018). Nano based drug delivery systems: re-cent developments and future prospects. J Nanobiotechnol, 16(1):1–33.
6. Xiao H, Yan L, Dempsey EM, et al (2018). Recent progress in polymer-based plati-num drug delivery systems. Progress Poly-mer Sci, 87(1):70–106.
7. Zalba S, Garrido MJ (2013). Liposomes, a promising strategy for clinical applica-tion of platinum derivatives. Expert Opin Drug Deliv,10(6):829–44.
8. Koukourakis MI, Giatromanolak A, Pitia-koudis M, et al (2010). Concurrent lipo-somal Cisplatin (Lipoplatin), 5-Fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Int J Radiat Oncol Biol Phys, 78(1): 150–55.
9. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos I (2006). Liposomal Ox-aliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res, 26(2B): 1489–93.
10. Nowotnik DP, Cvitkovic E (2009). Pro-lindac™ (AP5346): a review of the de-velopment of an HPMA DACH plati-num polymer terapeutic. Adv Drug Deliv Rev, 61(13): 1214–19.
2. Wang K, Gao E (2014). Recent advances in multinuclear complexes as potential an-ticancer and DNA binding agents. Anti-Cancer Agents Med Chem, 14(1):147–69.
3. Gibson D (2016). Platinum (IV) anticancer prodrugs – hypotheses and facts. Dalton Trans, 45(33): 12983–91.
4. Baudino TA (2015). Targeted cancer thera-py: the next generation of cancer treat-ment. Curr Drug Discov Technol, 12(1): 3–20.
5. Patra JK, Das G, Fraceto, LF, et al (2018). Nano based drug delivery systems: re-cent developments and future prospects. J Nanobiotechnol, 16(1):1–33.
6. Xiao H, Yan L, Dempsey EM, et al (2018). Recent progress in polymer-based plati-num drug delivery systems. Progress Poly-mer Sci, 87(1):70–106.
7. Zalba S, Garrido MJ (2013). Liposomes, a promising strategy for clinical applica-tion of platinum derivatives. Expert Opin Drug Deliv,10(6):829–44.
8. Koukourakis MI, Giatromanolak A, Pitia-koudis M, et al (2010). Concurrent lipo-somal Cisplatin (Lipoplatin), 5-Fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Int J Radiat Oncol Biol Phys, 78(1): 150–55.
9. Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos I (2006). Liposomal Ox-aliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res, 26(2B): 1489–93.
10. Nowotnik DP, Cvitkovic E (2009). Pro-lindac™ (AP5346): a review of the de-velopment of an HPMA DACH plati-num polymer terapeutic. Adv Drug Deliv Rev, 61(13): 1214–19.
| Files | ||
| Issue | Vol 52 No 8 (2023) | |
| Section | Letter to the Editor | |
| DOI | https://doi.org/10.18502/ijph.v52i8.13418 | |
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Ivanova S, Obreshkova D, Peikova L. Health Benefits of Modificated Multiplatinum Derivatives as Strategies for Overcoming the Cisplatin Resistance. Iran J Public Health. 2023;52(8):1776-1778.
